Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mass Spectroscopy, MRI Reveal New View of Body’s Response to Infection

By LabMedica International staff writers
Posted on 20 Aug 2012
A new imaging advance offers a three-dimensional (3D) window into the body’s response to infection--and the ability to detect the proteins involved in the response--could lead to innovative new biomarkers and therapeutic agents for infectious diseases.

Vanderbilt University (Nashville, TN, USA) scientists from many fields combined magnetic resonance imaging (MRI) and imaging mass spectrometry to visualize the inflammatory response to a bacterial infection in mice. More...
The techniques, described June 14, 2012, in the journal Cell Host & Microbe, provide insights into the characteristics of proteins not previously involved in the inflammatory response.

Access to distinctive resources at Vanderbilt made the unprecedented 3D infection imaging possible, according to Eric Skaar, PhD, Ernest Goodpasture chair in pathology and one of the senior coauthors of the study. “The studies in this paper couldn’t have happened at any other university, because the resources simply don’t exist at most schools,” Dr. Skaar said.

The resources include animal imaging technologies available through the Vanderbilt University Institute of Imaging Science (VUIIS), directed by John Gore, PhD, and imaging mass spectrometry technologies available through the Mass Spectrometry Research Center (MSRC), directed by Richard Caprioli, PhD, Drs. Gore and Caprioli are also senior coauthors of the paper.

Dr. Skaar and his team were interested in imaging infection in 3D--in the whole animal--while also being able to identify the proteins that are generated at sites of infection. Imaging mass spectrometry is a unique technology that directly measures proteins, lipids, and other metabolites and maps their distribution in a biopsy or other tissue sample. Ahmed Attia, PhD, a former member of Dr. Skaar’s group now on the faculty at Cairo University (Egypt), infected mice with Staphylococcus aureus, he then brought the infected animals to Daniel Colvin, PhD, in the VUIIS, who imaged them with magnetic resonance imaging (MRI). Kaitlin Schroeder and Erin Seeley, PhD, in the MSRC then conducted imaging mass spectrometry studies.

Fusing the two technologies and multiple data sets accurately required the expertise of Kevin Wilson, MESc, in the VUIIS, who developed algorithms to show consolidated 3D views of the inflammatory response. “This is another example of the multimodality approach we have been pursuing in general within the Imaging Institute,” Dr. Gore said.

The technologies allow the investigators to see one image of an infected animal, look at how proteins of the immune system are responding, and identify where the infected tissue is located, according to Dr. Skaar. “Part of the strength of this work is not where the research is now, but where it allows us to go from here.”

The scientists’ strategy now is to identify “proteins that are important at the interface between the host and the pathogen-- the battleground between the immune system and the bacteria,” Dr. Skaar said. The researchers will study the proteins they identify to discover new biomarkers for infection, which could improve diagnostic tools, or new targets for therapeutic intervention.

The technologies available through the MSRC and the VUIIS will be useful for any investigator interested in imaging the inflammatory response, which has roles in infectious diseases, cancer and autoimmune diseases, according to Dr. Skaar. Moreover, although the technology is not noninvasive--as imaging mass spectrometry requires tissue sections--it could be applied to tissues removed from patients, such as tumors.

“Imaging mass spectrometry is extremely valuable for the discovery process because it does not require a target-specific reagent such as an antibody--that is, you do not have to know in advance what you’re looking for in order to correlate molecular changes with disease outcome,” Dr. Caprioli said. “An area of intense interest is the application of this technology to molecular pathology.”

Related Links:

Vanderbilt University




Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.